CSF1 and hepatocellular carcinoma: Collectively, these results suggest that blocking the CCL2‐CSF1 signaling pathway downstream of ASH1L or directly inhibiting ASH1L enzymatic activity holds promise as a clinical approach for treating ASH1L‐mediated HCC.